Literature DB >> 24037723

Colistin therapy for multidrug-resistant Gram-negative infection: clinical outcome and risk factors.

Y H Jun1, S J Jeun, S H Kang, H J Choi.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24037723     DOI： 10.1007/s15010-013-0522-z

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  9 in total

1.  Acquisition of multidrug-resistant gram-negative bacteria: incidence and risk factors within a long-term care population.

Authors:  Erin O'Fallon; Ruth Kandel; Ruth Kandell; Robert Schreiber; Erika M C D'Agata
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

Review 2.  The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species.

Authors:  David L Paterson
Journal:  Clin Infect Dis       Date:  2006-09-01       Impact factor: 9.079

Review 3.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Authors:  Jian Li; Roger L Nation; John D Turnidge; Robert W Milne; Kingsley Coulthard; Craig R Rayner; David L Paterson
Journal:  Lancet Infect Dis       Date:  2006-09       Impact factor: 25.071

4.  Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients.

Authors:  Matthew E Falagas; Petros I Rafailidis; Elda Ioannidou; Vangelis G Alexiou; Dimitrios K Matthaiou; Drosos E Karageorgopoulos; Anastasios Kapaskelis; Dimitra Nikita; Argyris Michalopoulos
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

5.  Nephrotoxicity of intravenous colistin: a prospective evaluation.

Authors:  Matthew E Falagas; Konstantinos N Fragoulis; Sofia K Kasiakou; George J Sermaidis; Argyris Michalopoulos
Journal:  Int J Antimicrob Agents       Date:  2005-11-08       Impact factor: 5.283

6.  The role of diabetes mellitus in patients with bloodstream infections.

Authors:  M Stoeckle; C Kaech; A Trampuz; W Zimmerli
Journal:  Swiss Med Wkly       Date:  2008-09-06       Impact factor: 2.193

Review 7.  Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe.

Authors:  M Souli; I Galani; H Giamarellou
Journal:  Euro Surveill       Date:  2008-11-20

8.  Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009.

Authors:  Kyungwon Lee; Mi-Na Kim; Jae-Seok Kim; Hye Lim Hong; Jung Oak Kang; Jong Hee Shin; Yeon-Joon Park; Dongeun Yong; Seok Hoon Jeong; Yunsop Chong
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

9.  Renal and neurological side effects of colistin in critically ill patients.

Authors:  Herbert Spapen; Rita Jacobs; Viola Van Gorp; Joris Troubleyn; Patrick M Honoré
Journal:  Ann Intensive Care       Date:  2011-05-25       Impact factor: 6.925
  9 in total
  1 in total

Review 1.  Management and prevention of drug resistant infections in burn patients.

Authors:  Roohi Vinaik; Dalia Barayan; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Expert Rev Anti Infect Ther       Date:  2019-08-04       Impact factor: 5.091
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.